Sanofi Enter into an Exclusive License Agreement with Verastem Oncology to Develop and Commercialize Copiktra (duvelisib) for all Oncology Indications

Sanofi Enter into an Exclusive License Agreement with Verastem Oncology to Develop and Commercialize Copiktra (duvelisib) for all Oncology IndicationsSanofi Enter into an Exclusive License Agreement with Verastem Oncology to Develop and Commercialize Copiktra (duvelisib) for all Oncology Indications

Shots:

  • Verastem to receive $5M up front, $42M as development & commercial milestones and royalties on sales of Copiktra in the licensed territories. Sanofi to get exclusive rights to develop and commercialize Copiktra and hold the marketing authorization & product license in Russia and CIS, Turkey, the Middle East & Africa
  • The focus of the agreement is to expand Sanofi’s oncology portfolio in the emerging markets. Additionally, Sanofi has the right to collaborate with Verastem in global development & clinical activities of Copiktra
  • Copiktra is an oral PI3K inhibitor (dual inhibitor of PI3K-delta and PI3K-gamma) and has received the US FDA’s approval for R/R CLL/SLL prior treated with 2L therapies with accelerated approval for FL prior treated with 2L therapies

Click here to­ read full press release/ article | Ref: Verastem | Image: Verastem